Locations:
SearchAdvertisement
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access
Key learnings from DESTINY trials
Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors
Study of 401,576 patients reveals differences in cancer burdens as well as overall survival
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy
Large cohort study finds no reduction in survival for patients managed with active surveillance compared to treated patients
Two thirds of patients responded to CAR T-cell therapy
Belzutifan superior to everolimus in phase 3 clinical trial
Despite sicker patients, response rates of teclistamab in a real-world study were similar to those from a pivotal clinical trial
Investigational chimeric antigen receptor natural killer cell therapy NKX101 associated with promising early response in patients with relapsed/refractory acute myeloid leukemia
Advertisement
Advertisement